Laxative Properties of Microencapsulated Oleic Acid Delivered to the Distal Small Intestine in Patients with Constipation after Bariatric Surgery or Treatment with Glucagon-Like- Peptide 1 Analogues.

What Was Tested

This randomized controlled trial looks at Glucagon.

The researchers investigated whether oleic acid can ameliorate constipation in patients undergoing bariatric surgery or receiving GLP-1 analogues.

Why It Was Studied

Constipation is prevalent after bariatric surgery and glucagon-like-peptide 1 (GLP-1) analogues.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Fourteen adults with chronic constipation according to Rome IV criteria following bariatric surgery or GLP-1 analogues were on stable treatment for constipation for more than 4 weeks.

How the Study Was Run

In design terms this was a randomized, double-blind and crossover study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Glucagon, so expectations could not easily colour the readings.

In the crossover set-up each of the participants took both Glucagon and the comparison in turn, acting as their own control.

The primary outcome was changed in the number of bowel motions over 24 h.

Exploratory endpoints included alterations in straining, diarrhoea, faecal leakage over 24 h and hunger, fullness, nausea and calorie intake for the 3 h after ingesting the microcapsules.

What Was Measured

The subject headings attached to it are Constipation, Oleic Acid, Laxatives, Intestine, Small, Glucagon-Like Peptide 1, Obesity, Morbid and Capsules.

Author keywords: Bariatric surgery, Chronic constipation, GLP-1 analogues, Intentional weight-loss intervention and Olive oil.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Glucagon.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (Obesity surgery), a journal based in United States.

More context: the Glucagon compound page, all human trials.